LB Pharmaceuticals price target raised to $40 from $35 at Stifel

Stifel raised the firm’s price target on LB Pharmaceuticals (LBRX) to $40 from $35 and keeps a Buy rating on the shares. Following an in-line Q4 earnings report, the firm says it continues to view LB as “a compelling name with pipeline-in-a-product potential.”